Hansoh Pharma Drug Combination Improves Progression-Free Survival in Phase 3 Trial
Hansoh Pharma said dalmelitinib-aumolertinib improved progression-free survival in a Phase 3 lung cancer trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.